FY2025 · ended Dec 31, 2025 · Revenue $69.26M, -31.8% YoY · Filed Mar 26, 2026
Rockwell Medical, Inc. (RMTI) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $69.3 million and a net loss of $5.3 million. Free cash flow was -$1.2 million. As of Jun 30, 2026 it held $10.5 million in cash and investments and $13.9 million in total debt.
Revenue (TTM)
$69.39M
-21.1% vs year-ago TTM
Net income (TTM)
$-5.08M
-142.2% vs year-ago TTM
Operating cash flow (TTM)
$2.90M
-17.2% vs year-ago TTM
Free cash flow (TTM)
$1.54M
EPS (TTM)
$-0.14
-1.7% vs year-ago TTM
Dividend per share
None
Shares outstanding
39.41M
+15.7% vs prior year
Net cash
$-3.41M
as of Jun 30, 2026
Operating margin
-6.5%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- RMTI (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Wixom, MI
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1041024
- Former names
- ROCKWELL MEDICAL TECHNOLOGIES INC (until Jun 14, 2012)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $69.3M | $101.5M | $83.6M | $72.8M | $61.9M |
| Operating income | -$4.7M | $608,000 | -$6.7M | -$16.8M | -$30.3M |
| Net income | -$5.3M | -$480,000 | -$8.4M | -$18.7M | -$32.7M |
| Diluted EPS | -$0.15 | -$0.03 | -$0.37 | -$1.31 | -$3.83 |
| Operating cash flow | -$659,000 | $4.2M | -$9.4M | -$16.9M | -$33.5M |
| Free cash flow | -$1.2M | $3.2M | — | — | — |
| Total assets | $57.1M | $59.2M | $52.2M | $46.6M | $48.6M |
| Total liabilities | $20.2M | $26.6M | $30.9M | $32.5M | $46.0M |
| Stockholders' equity | $37.0M | $32.6M | $21.3M | $14.1M | $2.5M |
| Cash and investments | $25.0M | $21.6M | $10.9M | $21.5M | $22.4M |
| Total debt | $12.2M | $13.3M | $13.2M | $15.9M | $28.5M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement, Unregistered share sale, Regulation FD disclosure
|
Nov 3, 2026 | Nov 2, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Aug 13, 2026 | Aug 13, 2026 |
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 13, 2026 | Aug 13, 2026 |
| 8-K |
Current report
Other events
|
Jul 20, 2026 | Jul 20, 2026 |
| 8-K |
Current report
Change to shareholder rights, Bylaw or fiscal year change
|
Jun 29, 2026 | Jun 24, 2026 |
All 1000 Rockwell Medical, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.